Study Finds Manganese Balance is Crucial for Lyme Disease Bacterium Survival
By
gmays
Slow-proofed and worth the wait. Worth its weight in flour.
Summary
A new study reveals that the Lyme disease bacterium Borrelia burgdorferi relies on manganese as a 'double-edged sword' - the bacteria need manganese as an antioxidant to protect against the host's immune system, but both removing manganese or adding too much can weaken the pathogen. This discovery about manganese's delicate balance could lead to new treatment approaches for Lyme disease by disrupting this critical mineral equilibrium.
Key quotes
· 4 pulledLyme disease is caused by the bacterium Borrelia burgdorferi, which relies on the antioxidant manganese to protect it from its host's immune system.
Both removing or adding too much manganese weakens the bacteria.
Disrupting this balance could lead to new treatments for Lyme disease.
For decades, Lyme disease has frustrated both physicians and patients alike.
You might also wanna read
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
Spinach-derived photosynthetic treatment shows promise for dry eye disease
Scientists at the National University of Singapore have developed an experimental treatment for dry eye disease that uses photosynthetic mac
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
